Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms.
Ontology highlight
ABSTRACT: Neuroendocrine tumors (NETs) are highly vascularized malignancies in which angiogenesis may entail cell proliferation and survival. Among the emerging compounds with antivascular properties, cabozantinib (CAB) appeared promising. We analyzed the antitumor activity of CAB against NETs utilizing in vitro and in vivo models. For cell cultures, we used BON-1, NCI-H727 and NCI-H720 cell lines. Cell viability was assessed by manual count coupled with quantification of cell death, performed through fluorescence-activated cell sorting analysis as propidium iodide exclusion assay. In addition, we investigated the modulation of the antiapoptotic myeloid cell leukemia 1 protein under CAB exposure, as a putative adaptive pro-survival mechanism, and compared the responses with sunitinib. The activity o
SUBMITTER: Cella CA
PROVIDER: S-EPMC10644769 | biostudies-literature | 2023 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA